Skip to main content
. 2013 Oct 16;15(5):R95. doi: 10.1186/bcr3556

Table 3.

Risk of death of any cause or of breast cancer for adolescents and young adults (15 to 39 years of age) with breast cancer by tumor grade*, California, 2005-2009

  All-cause deaths
Breast cancer-specific deaths
Number of deaths HR (95% CI)* Number of deaths HR (95% CI)*
Low tumor grade (I/II)
 
 
 
 
 Subtype†
 
 
 
 
  HR+/HER2-
44
1.00 (reference)
27
1.00 (reference)
  HR+/HER2+
19
1.57 (0.87-2.81)
16
2.23 (1.12-4.44)
  HR-/HER2+
9
1.52 (0.61-3.76)
7
2.37 (0.85-6.61)
  Triple negative
25
10.64 (5.66-20.00)
21
13.87 (6.49-29.64)
  Unclassified
16
1.34 (0.70-2.57)
13
2.05 (0.95-4.44)
High tumor grade (III)
 
 
 
 
 Subtype†
 
 
 
 
  HR+/HER2-
73
1.00 (reference)
67
1.00 (reference)
  HR+/HER2+
23
0.49 (0.29-0.81)
21
0.48 (0.28-0.81)
  HR-/HER2+
59
1.40 (0.95-2.06)
55
1.40 (0.93-2.10)
  Triple negative
162
2.24 (1.61-3.13)
140
2.14 (1.51-3.04)
  Unclassified 57 1.47 (0.98-2.21) 49 1.32 (0.85-2.05)

* Cox models were adjusted for all variables presented in Table 2 and age at diagnosis (continuous), tumor size (continuous), and first course of treatment (chemotherapy (y/n), radiation (y/n), and surgery (y/n)); AJCC stage levels I-IV and unknown was included as a stratifying variable. P for interaction between breast cancer subtype and grade = 0.018 for all-cause mortality and =0.0735 for breast cancer-specific mortality.

† Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-negative).